CAR-T Cell Therapy Market- A Tale of Opportunities

As the number of cancer patients are mushrooming, scientists are coming up innovative ideas for the treatment of dreadful disease. A plethora of money is spent on the research and development and treatments such CAR T- Cell therapy are proving to be miraculous. In this blog we will discuss about the advantages of this therapy and why the CAR T- Cell therapy market is flourishing?

Table of Contents

What is CAR T- Cell therapy?

CAR T- Cell therapy is acronym for chimeric antigen receptor (CAR) T-Cell therapy. This is a type of treatment in which the T cell of a patient are taken out. The T cell is then attached with a special receptor which is called chimeric antigen receptor (CAR). A plenty of CAR T cell are produced in the laboratory and again fused in to the patient.

Therapy process-

  • T cells (immune cells) are collected from the patient.
  • T cells are then reengineered in a laboratory.
  • After the completion of the reengineering, T cells are known as “chimeric antigen receptor (CAR) T cells.”
  • The reengineered CAR T cells are then multiplied
  • At the treatment center or hospital, these CAR T cells are again thawed and infused into the patient
  • These infused CAR T cells may eliminate all the cancer cells and remain in the patients’ body for months after the infusion.

The report published by National Cancer Institute states that FDA-approved CAR T cell therapy treatment for leukemia, lymphoma, myeloma etc. Moreover, below written are the few names of the treatments-

  • Axicabtagene ciloleucel (Yescarta) is a treatment for adult patients suffering with large B-cell lymphoma.
  • Brexucabtagene autoleucel (Tecartus) is a treatment approved by FDA for the treatment of adult patients with relapsed cell lymphoma.
  • Idecabtagene vicleucel (Abecma) is a treatment approved by FDA for the treatment of myeloma.
  • Lisocabtagene maraleucel (Breyanzi) treatment is for large B-cell lymphoma approved by FDA
  • Tisagenlecleucel (Kymriah) is treatment for patients upto 25 years of age with B cell precursor acute lymphoblastic leukemia.
  • Tocilizumab (Actemra) is approved for the treatment of adults and pediatric patients with cytokine release syndrome (CRS).
See also  What Are the Things You Must Know About Good Service Tax?

The therapy is also available to the patients who are willing to participate in clinical trial for cancer. Although trial protocol varies for the patients.

Advantages of the therapy-

Before the advent of therapy, patients used to rely upon the stem cell transplant or the chemotherapy. Now patients have the choices to go for the treatment with more benefits. CAR T cell therapy has more benefits and lesser disadvantages. Below written are the benefits the therapy-

  • Treatment times: CAR T cell therapy require very short treatment times. It usually requires single infusion with less than two weeks of patient care. On the other hand, chemotherapy typically require months to complete and stem cells treatment also involve longer care.
  • Durability: Since CAR T cells persists in the body, these cells continue to treat cancer cells for longer period of time. The traditional chemotherapy is only effective only for a short period of administration.
  • Safety: CAR-T cell therapy does not require any aggressive chemotherapy. Also, unless there is an elevated cytokine rush following the infusion the cells do not typically require immunosuppression. This has proved to be an important safety advantage over chemotherapy and stem cell transplant.

Future of CAR T cell therapy-

Chimeric antigen receptor T cell trials have rendered remarkable results. The demand for the CAR T therapy as opposed to alternate therapies is rising the market. Its ability to treat multiple forms of lymphoma is a major factor for the popularity of the CAR T cell therapy treatment. The CAR T cell therapy market was valued at USD 1965.8 million in 2021. The CAGR is expected to grow by 31% by 2030.

See also  6 Important Features Of SEO For Growth Of Your CBD Business 

Wrapping up,

This very certain that the CAR-T cell therapy market is expected to hold promising future. The team of Research Nester has meticulously prepared a research report incorporating various imperative parameters such as growth drivers, market constraints, key players, latest news, etc. The report also consists of the regional synopsis conveying the geographic area holding promising opportunities for the market. It is always advisable to know the intricacies of the market.

By Vipul Rai

Leave a Reply

Your email address will not be published.